Switch theme
Sign up to access all valuation multiples
Glycorex Transplantation AB is a biotechnology company. The company is involved in the development, production, and sales of organ transplantation. Its product includes Glycosorb-ABO which facilitates the transplantation of organs over the blood group barriers. The group has more than 130 transplant centers in approximately 23 countries.
1996
22
Last FY Revenue $3.6M
Last FY EBITDA -$0.1M
$17.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Glycorex Transplantation achieved revenue of $3.6M and an EBITDA of -$0.1M.
Glycorex Transplantation expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Glycorex Transplantation valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $3.6M | XXX | XXX | XXX |
| Gross Profit | XXX | $2.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 80% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -3% | XXX | XXX | XXX |
| EBIT | XXX | -$1.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -30% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.1M | XXX | XXX | XXX |
| Net Margin | XXX | -31% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Glycorex Transplantation's stock price is SEK 2 (or $0).
Glycorex Transplantation has current market cap of SEK 181M (or $18.6M), and EV of SEK 172M (or $17.7M).
See Glycorex Transplantation trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.7M | $18.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Glycorex Transplantation has market cap of $18.6M and EV of $17.7M.
Glycorex Transplantation's trades at 4.9x EV/Revenue multiple, and -153.2x EV/EBITDA.
Equity research analysts estimate Glycorex Transplantation's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Glycorex Transplantation's P/E ratio is not available.
See valuation multiples for Glycorex Transplantation and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18.6M | XXX | $18.6M | XXX | XXX | XXX |
| EV (current) | $17.7M | XXX | $17.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -153.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -16.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -16.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1700.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGlycorex Transplantation's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Glycorex Transplantation's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Glycorex Transplantation's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Glycorex Transplantation and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -3% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 110% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Glycorex Transplantation acquired XXX companies to date.
Last acquisition by Glycorex Transplantation was XXXXXXXX, XXXXX XXXXX XXXXXX . Glycorex Transplantation acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Glycorex Transplantation founded? | Glycorex Transplantation was founded in 1996. |
| Where is Glycorex Transplantation headquartered? | Glycorex Transplantation is headquartered in Sweden. |
| How many employees does Glycorex Transplantation have? | As of today, Glycorex Transplantation has 22 employees. |
| Is Glycorex Transplantation publicy listed? | Yes, Glycorex Transplantation is a public company listed on NGM. |
| What is the stock symbol of Glycorex Transplantation? | Glycorex Transplantation trades under GTAB B ticker. |
| When did Glycorex Transplantation go public? | Glycorex Transplantation went public in 1999. |
| Who are competitors of Glycorex Transplantation? | Similar companies to Glycorex Transplantation include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Glycorex Transplantation? | Glycorex Transplantation's current market cap is $18.6M |
| Is Glycorex Transplantation profitable? | Yes, Glycorex Transplantation is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
